Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT06971822

Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults

Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults…

📅 28 Apr 2026 ⏱ 3 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06971822
Start
2025-03-14
Completion
2029-02-01
ClinicaliQ Trial Snapshot
  • Assessing the Impact of a Leucine Enriched Whey Protein vs Isonitrogenous Whey on Muscle Protein Synthetic Responses in the Rested and Acute Post Exercise States in Older Adults — Recruiting • Non-phase study • Diabetes / Metabolic • NCT06971822.
  • Testing whether leucine-enriched whey protein boosts muscle protein production in older adults at rest and after exercise, compared to standard whey protein.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Occupying ~45-55% of body mass, skeletal muscle is the largest organ of the body and plays a pivotal role in locomotion, structural support and whole-body metabolic health. Additionally, skeletal muscle serves as the largest reservoir of amino acids (AA), which negatively adapts in states of disease and fasting to provide energy and AAs for vital organs, but also positively adapts to nutrition (i.e. protein consumption) and exercise (i.e. resistance exercise (RE)). With the current global ageing population, pressure on health and social care systems is continuing to mount due to…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases
Diabetes / Metabolic · MHRA · 29 Jan 2026
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warni...
View brief →
Clinical Brief
GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse
Diabetes / Metabolic · MHRA · 24 Oct 2024
Healthcare professionals are reminded to inform patients about the common and serious side effects associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs). This…
View brief →
Clinical Brief
Insulin pumps and continuous glucose monitoring (CGM) equipment: guidance for users on reporting suspected adverse incidents and safety concerns to the MHRA’s Yellow Card scheme
Diabetes / Metabolic · MHRA · 24 Oct 2024
We ask healthcare professionals to support new guidance for users of diabetes management equipment, their families, care givers and representatives. This update…
View brief →
Clinical Brief
Why weight-loss jabs work better for some people than others
Diabetes / Metabolic · BBC Health · 10 Apr 2026
Genetic variations in appetite and digestion genes predict differential weight-loss responses to GLP-1 receptor agonists (Wegovy, Mounjaro), suggesting personalised medicine approaches may…
View brief →
Guideline
Tirzepatide for Managing Overweight and Obesity (NICE TA1026)
Diabetes / Metabolic · 27 Mar 2026
Prescribe tirzepatide to adults with BMI ≥35 kg/m² or BMI 30–34.9 kg/m² with weight-related comorbidities, initiating treatment in specialist weight management services…
View guideline →
Guideline
Semaglutide for Managing Overweight and Obesity (NICE TA875)
Diabetes / Metabolic · 27 Mar 2026
Initiate semaglutide only in specialist obesity services or via shared care with clear primary-secondary care protocols for adults with BMI ≥30 kg/m²…
View guideline →